Pediatric hepatocellular carcinoma (pediatric HCC) is a rare, aggressive, malignant hepatic tumor that develops mainly in children over 10 years of age.
Comprehensive, easy-to-understand information about this condition
How we create this content →Connect with organizations supporting the pediatric hepatocellular carcinoma community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the pediatric hepatocellular carcinoma community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the pediatric hepatocellular carcinoma community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 95 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning pediatric hepatocellular carcinoma
Updated Feb 16, 2026
A case study reports complete remission in a patient with advanced hepatocellular carcinoma following sequential therapy with durvalumab and cabozantinib. This finding may provide insights into effective treatment strategies for this challenging cancer.